Amphotericin B

Amphotericin B is a polyene antifungal antibiotic derived from the soil bacterium Streptomyces nodosus, representing one of the oldest and most potent antifungal agents available for treating severe systemic fungal infections in dogs and other species. First introduced in the 1950s, amphotericin B remains a cornerstone of therapy for life-threatening invasive fungal infections, often referred to as the gold standard against which newer antifungal agents are compared. The drug is used in veterinary medicine for treating serious systemic mycoses that pose significant threats to canine health, including blastomycosis, histoplasmosis, cryptococcosis, coccidioidomycosis, and aspergillosis. Due to its toxicity profile and the need for specialized administration protocols, amphotericin B therapy is typically initiated and monitored in veterinary hospital settings.

The mechanism of action of amphotericin B involves binding to ergosterol, a sterol component unique to fungal cell membranes that is analogous to cholesterol in mammalian cells. This binding creates pores in the fungal membrane, leading to leakage of essential ions and cellular contents, ultimately resulting in fungal cell death. The drug's fungicidal action distinguishes it from many azole antifungals, which are fungistatic. Amphotericin B's ability to rapidly kill fungal organisms makes it particularly valuable for treating severely ill patients where quick reduction of fungal burden is critical. However, because mammalian cell membranes also contain sterols, amphotericin B has inherent toxicity, particularly to kidney cells, which limits its use and requires careful monitoring.

Amphotericin B is available in several formulations with different characteristics and toxicity profiles. The conventional formulation, amphotericin B deoxycholate (Fungizone), is a complex with bile salts that has been used for decades but carries significant nephrotoxicity risk. Newer lipid-associated formulations, including amphotericin B lipid complex (Abelcet) and liposomal amphotericin B (AmBisome), were developed to reduce nephrotoxicity by encapsulating the drug in lipid particles that preferentially deliver it to fungal cells while reducing exposure to kidney tissue. These lipid formulations allow higher total doses to be administered with less kidney damage, though they are considerably more expensive than conventional amphotericin B.

Because amphotericin B is virtually unabsorbed from the gastrointestinal tract, it must be administered parenterally for systemic infections, typically by intravenous infusion. Subcutaneous administration protocols have also been developed to avoid the need for repeated intravenous catheterization, though this route may cause local tissue reactions. Treatment with amphotericin B requires hospitalization or frequent veterinary visits, intensive monitoring of kidney function, and careful attention to hydration status. The drug is typically used for initial treatment of severe fungal infections, with oral azole antifungals often employed for step-down therapy once the patient is stabilized. Despite newer antifungal options, amphotericin B remains an essential medication for managing serious systemic mycoses in dogs.

Amphotericin B is indicated in dogs for the treatment of severe systemic fungal infections caused by susceptible organisms, particularly when rapid fungicidal action is needed or when oral antifungal therapy is not feasible or has failed. The drug demonstrates broad-spectrum activity against the major pathogenic fungi encountered in veterinary medicine, including dimorphic fungi that cause endemic mycoses and various opportunistic fungal pathogens. Amphotericin B is typically reserved for life-threatening infections or situations where the severity of disease warrants its use despite the associated toxicity risks.

Blastomycosis, caused by the fungus Blastomyces dermatitidis, represents one of the most common indications for amphotericin B therapy in dogs in endemic regions. This infection, acquired through inhalation of fungal spores from contaminated soil, can cause severe pulmonary disease and disseminate to involve skin, eyes, bones, lymph nodes, and other organs. Dogs with severe respiratory compromise, extensive disseminated disease, or central nervous system involvement may benefit from initial treatment with amphotericin B, which provides rapid fungicidal activity. Studies have demonstrated high cure rates in dogs with blastomycosis treated with lipid-complexed amphotericin B formulations.

Histoplasmosis, caused by Histoplasma capsulatum, is another endemic mycosis for which amphotericin B may be employed, particularly in dogs with gastrointestinal involvement or severe disease. Dogs with histoplasmosis affecting the intestinal tract may have malabsorption that precludes effective oral antifungal therapy, making amphotericin B an important option for initiating treatment until intestinal function recovers. Cryptococcosis, caused by Cryptococcus neoformans or related species, may also require amphotericin B therapy, especially when the central nervous system is involved. Coccidioidomycosis (Valley Fever), prevalent in the southwestern United States, may be treated with amphotericin B in severe cases, though azole antifungals are more commonly used for this infection.

Amphotericin B is also employed for treating various invasive mold infections, including aspergillosis in its disseminated form. While nasal aspergillosis in dogs is typically treated with topical antifungal therapy, disseminated aspergillosis requires systemic treatment where amphotericin B may be combined with azole antifungals. Other fungal infections that may respond to amphotericin B include sporotrichosis in its systemic form, certain hyalohyphomycoses and phaeohyphomycoses caused by opportunistic molds, zygomycoses, and disseminated candidiasis. The drug's broad antifungal spectrum makes it valuable for treating rare or unusual fungal infections where organism identification may be delayed or where empiric therapy is needed.

Veterinarians select amphotericin B in specific clinical circumstances based on multiple factors. The drug is generally reserved for severe, life-threatening fungal infections where its rapid fungicidal action provides advantages over slower-acting oral agents. Patients too ill to take oral medications, those with gastrointestinal disease preventing drug absorption, or those who have failed oral antifungal therapy may require amphotericin B. The availability and cost of different formulations influence treatment decisions, with lipid formulations preferred for their reduced nephrotoxicity but conventional amphotericin B sometimes used due to cost considerations. Step-down to oral azole therapy typically follows initial amphotericin B treatment once the patient stabilizes.

The dosing and administration of amphotericin B in dogs requires specialized veterinary expertise, as the drug's significant toxicity potential mandates careful patient selection, intensive monitoring, and adherence to established protocols. Amphotericin B therapy is typically initiated and supervised in veterinary hospital settings where appropriate monitoring capabilities exist. The veterinarian will determine the specific formulation, dose, and administration schedule based on the type and severity of infection, the patient's kidney function, and available resources. This medication should never be administered by owners at home; professional veterinary administration is required.

Dosing of conventional amphotericin B deoxycholate in dogs typically begins at 0.5 milligrams per kilogram of body weight per dose, administered intravenously over several hours. The dose may be increased gradually to 1 mg/kg as tolerated. Treatment is typically administered every 48 hours (every other day) or three times weekly, allowing time for kidney recovery between doses. Cumulative doses for conventional amphotericin B typically range from 4 to 8 mg/kg total in dogs, though treatment may be stopped earlier if significant nephrotoxicity develops. The lipid formulations allow higher individual and cumulative doses: typical dosing for lipid complex formulations is 1 to 2 mg/kg every other day, with cumulative doses up to 24 mg/kg or higher tolerated in dogs.

Treatment duration with amphotericin B varies depending on the type of infection, disease severity, and patient response. For most systemic mycoses, amphotericin B is administered until clinical improvement is evident and the patient can be transitioned to oral antifungal therapy for long-term treatment. Some protocols specify target cumulative doses, while others use clinical response and laboratory monitoring to guide treatment duration. Blastomycosis and histoplasmosis may require cumulative doses at the higher end of the range for optimal outcomes. The total duration of antifungal therapy, including subsequent oral treatment, typically extends for months, with the amphotericin B component representing the initial intensive phase.

Administration of amphotericin B requires careful preparation and specific protocols to minimize toxicity. The drug must be properly reconstituted and diluted according to manufacturer instructions, using dextrose solutions (not saline, which causes precipitation with conventional formulations). Intravenous infusions are administered slowly over 2 to 6 hours to reduce infusion-related reactions. The patient should be well-hydrated before each dose to protect kidney function, and intravenous fluids at approximately twice maintenance rates are typically administered before and after drug infusion. Kidney values (BUN, creatinine) and electrolytes should be evaluated before each dose, and treatment is delayed if kidney parameters are increasing even within the normal range.

Subcutaneous administration protocols have been developed as an alternative to repeated intravenous access, though this route is associated with local tissue irritation. For subcutaneous administration, amphotericin B deoxycholate is diluted in an appropriate volume of fluid (typically 400-500 mL for dogs) at concentrations below those that cause significant local reactions. This approach can reduce the need for frequent intravenous catheterization but may cause sterile abscesses at injection sites. The subcutaneous route is generally reserved for situations where repeated intravenous access is not feasible.

Monitoring during amphotericin B therapy is intensive and essential for patient safety. Before initiating treatment, baseline kidney function tests, complete blood count, and electrolyte panel should be obtained. Before each dose, kidney values are rechecked, and treatment is held if values are increasing significantly. Electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, may occur and require supplementation. Vital signs should be monitored during infusions for signs of acute reactions. Clinical response to treatment is assessed through improvement in symptoms, radiographic changes, and when available, antigen testing for specific fungal infections.

Amphotericin B is associated with significant adverse effects, most notably nephrotoxicity, which is the dose-limiting toxicity of this medication and requires intensive monitoring throughout treatment. Understanding the potential side effects helps veterinary teams anticipate problems and implement monitoring and supportive care protocols that optimize patient safety. While newer lipid formulations have improved the safety profile compared to conventional amphotericin B, all formulations carry risks that must be weighed against the benefits of treating life-threatening fungal infections.

Nephrotoxicity is the most significant adverse effect of amphotericin B therapy in dogs and occurs to some degree in most patients receiving the conventional deoxycholate formulation. The drug causes vasoconstriction of renal blood vessels and direct toxic effects on kidney tubular cells, leading to decreased glomerular filtration rate and impaired kidney function. Blood urea nitrogen (BUN) and creatinine levels typically increase during treatment, and therapy must be paused or discontinued if these values rise excessively. Acute kidney injury can occur, and some patients may develop chronic kidney disease following treatment. Lipid formulations substantially reduce but do not eliminate nephrotoxicity, allowing higher cumulative doses with less kidney damage. Aggressive hydration before and after each dose is the primary strategy for minimizing renal toxicity.

Electrolyte abnormalities commonly occur during amphotericin B therapy as a consequence of kidney effects and direct drug actions. Hypokalemia (low potassium) is particularly common and may cause muscle weakness, cardiac arrhythmias, and other complications if not addressed through supplementation. Hypomagnesemia (low magnesium) can also occur and may exacerbate potassium losses. Regular monitoring of electrolyte levels and appropriate supplementation are essential components of amphotericin B treatment protocols. Renal tubular acidosis and impaired urinary concentrating ability may also develop.

Infusion-related reactions occur in some patients during or shortly after amphotericin B administration. These reactions may include fever, chills, nausea, vomiting, and hypotension. Slower infusion rates and premedication with antihistamines, antipyretics, or low-dose corticosteroids may reduce these reactions. Phlebitis (vein inflammation) can occur at intravenous catheter sites, and proper technique and site care help minimize this complication. Subcutaneous administration may cause local tissue reactions including swelling, pain, and sterile abscess formation at injection sites.

Other adverse effects of amphotericin B include anemia, which develops in many patients during treatment due to the drug's effects on red blood cell production and potentially increased destruction. Anorexia and gastrointestinal upset may occur, affecting nutritional status in already compromised patients. Cardiac arrhythmias are possible, particularly in patients with electrolyte abnormalities. Hepatotoxicity occurs less commonly than nephrotoxicity but liver enzyme monitoring is advisable. Severe reactions, while uncommon with appropriate administration protocols, require immediate veterinary attention. Owners should understand that hospitalization or frequent veterinary visits are necessary during amphotericin B therapy to monitor for and manage these potentially serious adverse effects.

Amphotericin B is contraindicated in dogs with known hypersensitivity or severe previous reactions to the drug or its formulation components. Dogs that have experienced serious adverse reactions to any amphotericin B formulation, including anaphylaxis or other severe hypersensitivity responses, should not receive the drug. Any history of allergic reactions to medications should be disclosed to the veterinary team before treatment is considered. Cross-reactivity between different amphotericin B formulations may occur, though some patients who react to conventional formulations may tolerate lipid preparations.

Pre-existing severe kidney disease represents a significant contraindication to amphotericin B therapy in most circumstances. Because the drug is inherently nephrotoxic, administering it to patients with already compromised kidney function carries substantial risk of worsening renal impairment or precipitating acute kidney failure. Veterinarians will evaluate kidney function before initiating therapy, and dogs with significantly elevated creatinine or BUN levels may require alternative antifungal treatment or careful risk-benefit assessment. If amphotericin B is deemed essential despite kidney concerns, lipid formulations and aggressive supportive care may somewhat reduce but not eliminate the risks. Sequential or concurrent nephrotoxic drug use should be avoided.

The use of amphotericin B concurrently with other nephrotoxic medications should generally be avoided due to the risk of additive kidney damage. Aminoglycoside antibiotics, certain nonsteroidal anti-inflammatory drugs, and other potentially nephrotoxic agents should be used with extreme caution or avoided during amphotericin B therapy. The veterinarian will review all current medications to identify potential interactions that could increase nephrotoxicity risk. If concurrent nephrotoxic therapy is necessary, more intensive renal monitoring and modified dosing protocols may be required.

The safety of amphotericin B during pregnancy in dogs has not been established, and the drug should be avoided in pregnant animals unless the life-threatening nature of the fungal infection justifies the risks. Amphotericin B crosses the placenta, and effects on developing fetuses are a concern. Lactating dogs treated with amphotericin B should not nurse puppies during treatment. Other relative contraindications include severe debilitation, dehydration (which should be corrected before treatment), and situations where appropriate monitoring cannot be provided. Amphotericin B therapy requires veterinary oversight and monitoring capabilities; it should not be attempted without adequate resources for patient surveillance and supportive care.

Providing the veterinary team with a complete list of all medications, supplements, and other treatments the dog is receiving is essential before initiating amphotericin B therapy. Drug interactions with amphotericin B can significantly increase toxicity risk, reduce drug effectiveness, or complicate management of the patient's condition. The veterinary team needs complete information to identify potential interactions, adjust treatment protocols, and implement appropriate monitoring. Given the intensive nature of amphotericin B therapy, careful coordination of all medications is critical for patient safety.

The most clinically significant drug interactions with amphotericin B involve other nephrotoxic agents. Concurrent administration of aminoglycoside antibiotics (such as gentamicin or amikacin), certain nonsteroidal anti-inflammatory drugs, cyclosporine, or other potentially nephrotoxic medications can substantially increase the risk of kidney damage. These combinations should be avoided when possible, or if necessary, require intensive renal monitoring and possibly dose modifications. Diuretics such as furosemide, which are sometimes used to promote urine flow, may also interact by affecting fluid and electrolyte balance, potentially exacerbating hypokalemia.

Interactions affecting amphotericin B's antifungal activity have been investigated, particularly regarding concurrent use with azole antifungals. In vitro studies have suggested potential antagonism between amphotericin B and azoles because amphotericin B targets ergosterol while azoles inhibit ergosterol synthesis; if ergosterol is reduced, amphotericin B may have less target to bind. However, the clinical significance of this interaction is debated, and in practice, sequential therapy (amphotericin B followed by azoles) is a standard approach. Concurrent administration of both drug classes is generally avoided, with step-down to azole therapy occurring after amphotericin B treatment is completed.

Electrolyte-depleting medications interact with amphotericin B by potentially exacerbating drug-induced electrolyte abnormalities. Corticosteroids, which may be used for various indications in dogs with systemic illness, can cause potassium and fluid shifts that compound amphotericin B effects. Careful electrolyte monitoring and supplementation are necessary when these drugs are used together. Cardiac glycosides such as digoxin, if used, may have enhanced toxicity in the presence of hypokalemia caused by amphotericin B, requiring vigilant monitoring.

Monitoring for drug interactions during amphotericin B therapy is incorporated into the overall intensive monitoring required for this treatment. Renal function tests, electrolytes, and clinical status are evaluated regularly, providing opportunities to detect interaction-related problems. Any new medications should be evaluated for interaction potential before addition to the treatment regimen. The veterinary team will coordinate all aspects of the patient's care to minimize interaction risks while optimizing treatment of the underlying fungal infection.

Standard precautions for amphotericin B use include recognition that this is a high-risk medication requiring specialized veterinary expertise, intensive monitoring, and appropriate treatment setting. The drug should only be administered under direct veterinary supervision, typically in a hospital environment where monitoring capabilities and emergency support are available. Owners should understand that amphotericin B therapy involves significant commitment in terms of time, cost, and the need for repeated veterinary visits or hospitalization. The decision to use amphotericin B should involve thorough discussion of risks, benefits, alternatives, and the overall treatment plan for managing the fungal infection.

While specific breed-related concerns with amphotericin B are not as pronounced as with some other medications, general considerations for critically ill patients of any breed apply. German Shepherds and Rhodesian Ridgebacks appear predisposed to disseminated aspergillosis, and American Cocker Spaniels may be predisposed to cryptococcosis. Dogs of any breed with pre-existing conditions affecting kidney function face increased risk of nephrotoxicity. The MDR1 (ABCB1) gene mutation common in herding breeds does not have well-documented interactions with amphotericin B, but any breed predispositions or genetic sensitivities should be communicated to the veterinary team as part of comprehensive patient evaluation.

Environmental and handling precautions are primarily relevant to veterinary staff preparing and administering amphotericin B. The drug should be reconstituted and diluted according to strict protocols to prevent precipitation and ensure proper delivery. Extravasation (leakage from veins) can cause significant local tissue damage and should be prevented through careful intravenous technique. For subcutaneous administration protocols, appropriate dilution is necessary to minimize local tissue reactions. Personnel handling amphotericin B should use standard precautions for injectable medications.

Monitoring during amphotericin B therapy is mandatory and intensive. Pre-treatment evaluation includes baseline kidney function tests (BUN, creatinine), complete blood count, electrolyte panel, liver enzymes, and assessment of the patient's overall condition. Before each dose, kidney values and electrolytes are rechecked, and treatment is delayed if parameters indicate developing nephrotoxicity. During infusions, vital signs are monitored for infusion reactions. Between treatments, the patient is monitored for clinical improvement in the underlying fungal infection as well as any signs of drug toxicity. Regular reassessment helps guide decisions about treatment continuation, dose modification, or transition to oral antifungal therapy.

Special populations requiring additional consideration include geriatric dogs with age-related decline in kidney function, dogs with any pre-existing renal impairment, and severely debilitated patients who may have reduced physiological reserves to cope with drug toxicity. Puppies and young dogs with fungal infections may be treated with amphotericin B when indicated, though their developing physiology requires attention. Pregnant dogs should not receive amphotericin B unless the fungal infection poses an immediate threat to life. Dogs with cardiac disease require careful monitoring of fluid administration and electrolytes during treatment.

Proper storage of amphotericin B is essential for maintaining drug stability and effectiveness. The specific storage requirements vary by formulation and product, and the manufacturer's instructions should be followed precisely. Conventional amphotericin B deoxycholate for injection is typically stored under refrigeration (2 to 8 degrees Celsius or 36 to 46 degrees Fahrenheit) and protected from light. The lipid formulations (Abelcet, AmBisome) have their own storage requirements specified on product labeling. Once reconstituted, amphotericin B solutions have limited stability and must be used within specified timeframes. Liposomal formulations may be stable for at least one week if refrigerated and handled aseptically.

Preparation of amphotericin B for administration requires careful attention to reconstitution and dilution procedures. The drug should only be reconstituted with the diluents specified by the manufacturer, as incompatible solutions can cause precipitation or inactivation. Conventional amphotericin B deoxycholate is typically reconstituted with sterile water, then further diluted in 5% dextrose (not saline, which is incompatible). The final solution should be inspected for particulate matter or discoloration before use. Lipid formulations have specific reconstitution procedures that must be followed, including proper shaking to ensure uniform suspension. Filtration requirements vary by formulation.

Handling of amphotericin B during preparation and administration follows standard protocols for injectable medications. Aseptic technique prevents contamination of solutions that will be administered intravenously. Personal protective equipment appropriate for handling injectable medications should be used by veterinary staff. The drug and prepared solutions should be protected from light during storage and administration, as light exposure can degrade the product. Incompatibility with numerous other drugs and solutions means that amphotericin B should be administered through dedicated intravenous lines or with appropriate flushing between incompatible medications.

Disposal of unused amphotericin B should follow institutional protocols for pharmaceutical waste. Expired or contaminated products should not be used and should be disposed of properly. Given the high cost of lipid formulations, efficient use of reconstituted products within their stability windows maximizes value while ensuring safety. Empty vials and administration sets should be disposed of according to biohazardous waste guidelines when appropriate. Any spills should be cleaned according to standard procedures for chemotherapy or hazardous drug cleanup, depending on institutional classification.

Amphotericin B may be used in dogs of any breed when severe systemic fungal infections require its potent antifungal activity, with individual patient factors being more important than breed-specific considerations for most treatment decisions. The drug's use is determined primarily by the nature and severity of the fungal infection rather than breed characteristics. However, certain breed predispositions to specific fungal diseases and breed-related health factors may influence treatment planning and monitoring intensity during amphotericin B therapy.

Certain breed predispositions to fungal infections have been noted in veterinary literature. German Shepherd Dogs appear overrepresented among dogs developing disseminated aspergillosis, a serious condition that may require amphotericin B as part of treatment. Rhodesian Ridgebacks also show increased susceptibility to this form of aspergillosis. American Cocker Spaniels may have higher rates of cryptococcosis in some geographic areas. Large-breed and sporting dogs that spend significant time outdoors in endemic areas may have increased exposure risk for blastomycosis and histoplasmosis. These breed associations affect the likelihood of encountering fungal infections that might require amphotericin B rather than the drug's safety or efficacy in specific breeds.

Genetic variations affecting drug handling, while not specifically documented to alter amphotericin B pharmacology, represent background considerations in veterinary pharmacotherapy. The MDR1 (ABCB1) gene mutation common in Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, and related breeds affects the transport of certain drugs, though amphotericin B is not among those commonly implicated in MDR1-related toxicity. Dogs with known breed predispositions to kidney disease should have careful renal evaluation before amphotericin B therapy, as pre-existing nephropathy increases the risk of drug-induced kidney damage.

Size considerations affect practical aspects of amphotericin B administration. Giant breed dogs require larger fluid volumes for drug dilution and supportive hydration, potentially complicating fluid management. Toy breeds may be more susceptible to fluid overload and require careful attention to total fluid administration. Drug dosing is calculated on a milligram per kilogram basis regardless of breed, with accurate body weight measurement essential for proper dose calculation. Age-related factors apply across all breeds: geriatric dogs commonly have some degree of reduced kidney function that increases nephrotoxicity risk, while young dogs may have developing organ systems. Any individual patient's overall health status and concurrent conditions are more important than breed in determining treatment approach and monitoring intensity during amphotericin B therapy.

Amphotericin B belongs to the polyene class of antifungal drugs, which also includes nystatin and natamycin. These related compounds share the mechanism of binding to fungal membrane ergosterol but differ in their clinical applications. Nystatin is used topically for superficial yeast infections because it is too toxic for systemic use and is not absorbed orally. Natamycin is used primarily as an ophthalmic antifungal. Among the polyenes, amphotericin B is the only agent suitable for treating systemic fungal infections, making it unique despite its toxicity profile.

Azole antifungals represent the primary alternative and complementary drug class for treating systemic fungal infections in dogs. Itraconazole is commonly used for blastomycosis, histoplasmosis, and other systemic mycoses, often as step-down therapy following initial amphotericin B treatment or as first-line therapy for less severe infections. Fluconazole is particularly valuable for cryptococcosis and other infections involving the central nervous system due to its excellent penetration across the blood-brain barrier. Ketoconazole, while less commonly used due to higher toxicity rates and less potent antifungal activity, remains an option in some situations. Newer azoles such as voriconazole and posaconazole are available for resistant infections or as salvage therapy but are expensive and have limited veterinary data. The azoles are fungistatic rather than fungicidal, which is one reason amphotericin B is preferred for severe infections where rapid fungal killing is important.

Complementary and supportive therapies are essential components of treating dogs with serious systemic fungal infections. Aggressive fluid therapy before and after amphotericin B doses helps protect kidney function and is a cornerstone of treatment protocols. Electrolyte supplementation, particularly potassium, addresses drug-induced imbalances. Nutritional support may be necessary for debilitated patients, and antiemetic or appetite-stimulating medications may help maintain nutrition during treatment. For specific manifestations of fungal disease, additional interventions such as surgical debridement of localized lesions, ocular medications for uveitis, or anti-inflammatory therapy for excessive inflammation may be indicated. The overall treatment plan for systemic mycoses typically combines initial intensive therapy (often including amphotericin B for severe cases) with prolonged oral azole therapy lasting months, along with supportive care tailored to the individual patient's needs.